Abstract
Objective: The enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase catalyses the rate-limiting step in cholesterol biosynthesis. Until now, there has been no evidence for a possible correlation between HMG-CoA reductase activity and human liver disease. The objective of this study was to test whether HMG-CoA reductase activity is altered in cryptogenic fatty liver disease. Method: We measured this enzyme activity in liver tissue of 20 patients undergoing routine transcutaneous biopsy of the liver (10 patients with cryptogenic fatty liver disease, three with alcoholic fatty liver disease, two with chronic hepatitis and five with normal histology)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European Journal of Gastroenterology & Hepatology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.